Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Healthy male volunteers, age between 20 and 45

• Informed of the investigational nature of this study and voluntarily agree to participate in this study

• BMI of >20kg/m2 and <26kg/m2 subject

Exclusion Criteria:

• Use of any prescription medication within 14 days prior to Day 1

• Use of any medication within 7 days prior to Day 1

• Participation in another clinical study within 60 days prior to start of study drug administration